← Back to Clinical Trials
Recruiting NCT03192267

NCT03192267 Early Rheumatoid Arthritis Lung Disease Study

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT03192267
Status Recruiting
Phase
Sponsor University of Nebraska
Condition Rheumatoid Arthritis
Study Type OBSERVATIONAL
Enrollment 125 participants
Start Date 2017-03-31
Primary Completion 2029-03

Eligibility & Interventions

Sex All sexes
Min Age 19 Years
Max Age 90 Years
Study Type OBSERVATIONAL

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 125 participants in total. It began in 2017-03-31 with a primary completion date of 2029-03.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Extra-articular (outside of joints) disease occurs in approximately 50% of rheumatoid arthritis (RA) patients, with the lung being a common site of involvement. The goals of this study are to investigate and characterize lung disease and its prevalence in early RA participants. This will be done through pulmonary function and high resolution chest computed tomography (CT), questionnaires, and serum studies. Another goal is to find novel biomarkers, such anti-malondialdehyde-acetaldehyde (MAA) antibodies, as predictors of lung disease in RA participants.

Eligibility Criteria

Inclusion Criteria: * 19-90 years of age * Able to give informed consent * Diagnosis of RA by a Rheumatologist using 2010 American College of Rheumatology (ACR) criteria within the past 2 years Exclusion Criteria: * Inflammatory arthritis that does not meet 2010 American College of Rheumatology (ACR) criteria for rheumatoid arthritis (RA) * Pregnant

Contact & Investigator

Central Contact

Aimee B Schreiner, MS

✉ aischreiner@unmc.edu

📞 402-559-4873

Principal Investigator

Tina D Mahajan, MD

STUDY CHAIR

University of Nebraska

Frequently Asked Questions

Who can join the NCT03192267 clinical trial?

This trial is open to participants of all sexes, aged 19 Years or older, up to 90 Years, studying Rheumatoid Arthritis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT03192267 currently recruiting?

Yes, NCT03192267 is actively recruiting participants. Contact the research team at aischreiner@unmc.edu for enrollment information.

Where is the NCT03192267 trial being conducted?

This trial is being conducted at Omaha, United States.

Who is sponsoring the NCT03192267 clinical trial?

NCT03192267 is sponsored by University of Nebraska. The principal investigator is Tina D Mahajan, MD at University of Nebraska. The trial plans to enroll 125 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology